Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

Part of paid clinical trials in Royal Oak, Michigan.

Sponsor
Associated Retinal Consultants, Michigan
Study ID
NCT02291887
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Ranibizumab — DRUG
    Intravitreal injection of Ranibizumab
  • Aflibercept — DRUG
    Intravitreal injection of Aflibercept

Study Details

A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing. The sequencing data will be compiled and analyzed in an attempt to identify a common genetic basis for patients susceptible to ranibizumab but resistant to aflibercept.

Key Dates

Start date
Dec 22, 2014
Status verified
Nov 2017
Primary completion
Jul 1, 2015
Completion
Jul 1, 2015

Study Design

Enrollment
13 participants (actual)

Arms

  • Arm: Neovascular ARMD Patients
    Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment

Primary Outcome Measure

Genetic characteristics of patients responsive to Ranibizumab but Resistant to Aflibercept [ Time Frame: 1 day ]

Locations (1)

FacilityCityStateZIPSite coordinators
Associated Retinal ConsultantsRoyal OakMichigan48073-

Find similar trials in Royal Oak, MI

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Associated Retinal Consultants· Royal Oak, MI

Related Studies